Parkinson's Disease Newswire (Page 8)

Parkinson's Disease Newswire (Page 8)

Comprehensive Real-Time News Feed for Parkinson's Disease. (Page 8)

Results 141 - 160 of 53,809 in Parkinson's Disease

  1. Pesticide use in agriculture and Parkinson's disease in the AGRICAN cohort study.Read the original story

    Wednesday Nov 15 | CiteULike

    Epidemiological studies have reported an increased risk of Parkinson's disease in farmers exposed to pesticides, but no clear conclusion can be drawn on the type of pesticide and duration of use associated with an effect. In the French agricultural cohort AGRICAN, we assessed associations between PD and pesticide use according to the types of livestock and crops grown, including exposure to some active ingredients with duration of use.

    Comment?

  2. MiRNAs participate in the diagnosis, pathogenesis and therapy of Parkinson's disease.Read the original story

    Wednesday Nov 15 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. MicroRNAs , one kind of post-transcriptional modification, mediate transcriptional silencing of various metabolic enzymes that are involved in various life processes, including Parkinson's disease.

    Comment?

  3. Mechanistic contributions of FBXO7 to Parkinson's disease.Read the original story

    Wednesday Nov 15 | CiteULike

    Parkinson's disease is, without doubt, a burden on modern society as the prevalence increases significantly with age. Owing to this growing number of PD cases, it is more critical than ever to understand the pathogenic mechanisms underlying PD to identify therapeutic targets.

    Comment?

  4. Acorda Therapeutics, Inc. (ACOR) Given Hold Rating at Cantor FitzgeraldRead the original story w/Photo

    Wednesday Nov 15 | Daily Political

    ... monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson's disease (PD)."" Several other research firms also recently commented on ACOR. Oppenheimer Holdings, Inc. began coverage on Acorda ...

    Comment?

  5. Cantor Fitzgerald Reiterates Hold Rating for Acorda Therapeutics, Inc.Read the original story w/Photo

    Wednesday Nov 15 | AmericanBankingNews.com

    ... monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson's disease (PD)."" Several other equities research analysts also recently weighed in on the company. Cowen and Company reiterated a "buy" ...

    Comment?

  6. Virtual reality training may be as effective as regular therapy after strokeRead the original story w/Photo

    Wednesday Nov 15 | PhysOrg Weblog

    ... reality and treadmill training may prove effective in preventing dangerous falls associated with aging, Parkinson's disease, mild cognitive impairment or dementia, according to a new Tel Aviv University-Tel ... Research by a group of scientists at ...

    Comment?

  7. Scientists sniff out new treatment for Alzheimer's; new research...Read the original story w/Photo

    Wednesday Nov 15 | NewsTarget.com

    ... the potential of using worms in order to identify potential treatments for Alzheimer's disease and Parkinson's disease. As part of the two-year project, the worms will be given human genes associated with the neurodegenerative diseases. The ...

    Comment?

  8. Parkinson disease polygenic risk score is associated with Parkinson...Read the original story w/Photo

    Tuesday Nov 14 | BioMed Central

    The genetic architecture of Parkinson's Disease is complex and not completely understood. Multiple genetic studies to date have identified multiple causal genes and risk loci.

    Comment?

  9. New Holiday Event: West Seattle Track FridayRead the original story w/Photo

    Wednesday Nov 15 | West Seattle Blog

    ... day that has become synonymous with commercialism. P3 owner Michele Pettinger is raising money to fight Parkinson's Disease , which her mom has, but you can choose your own charity too. You can just show up between 9 and 11 and walk/run whatever you ...

    Comment?

  10. Acadia Pharmaceuticals: Risky, But Potentially Very LucrativeRead the original story w/Photo

    Wednesday Nov 15 | Seeking Alpha

    ... received FDA approval for NUPLAZID in March of 2016 to treat patients with psychosis associated with Parkinson's disease. Parkinson's affects about a million people in the US alone, of which 40% has a related disease psychosis. The company reported ...

    Comment?

  11. Drugmaker Acorda Plunges After Deaths in Parkinson's TrialRead the original story

    Wednesday Nov 15 | The Washington Post

    Acorda Therapeutics Inc. plunged by a record 40 percent after patients died in final-stage studies of a treatment for Parkinson's disease, in a fresh blow to a drugmaker that had started to rebound from earlier setbacks. Seven patients in the trial developed a severe blood infection called Sepsis, and five of them died, Acorda said in a statement on Wednesday.

    Comment?

  12. Acorda Shares Plunge After Deaths in Parkinson's TrialRead the original story w/Photo

    Wednesday Nov 15 | News Max

    Acorda Therapeutics Inc. said it halted enrolling patients in two late-stage safety studies of its Parkinson's disease drug following deaths, sending its shares tumbling more than 40 percent in premarket trading. The company said five people died in mid- and late-stage trials following seven cases of sepsis, with four associated with agranulocytosis - the absence of white blood cells.

    Comment?

  13. UPDATE 2-Acorda reports deaths in Parkinson's trial, shares plungeRead the original story w/Photo

    Wednesday Nov 15 | Reuters

    Acorda Therapeutics Inc said on Wednesday five people died in its Parkinson's disease drug trials, and it would stop enrolling new patients in two long-term safety studies, sending its shares down 34 percent in early trade. The company, testing tozadenant, said in the mid-and late-stage trials it found seven cases of sepsis, with four associated with agranulocytosis - the absence of white blood cells.

    Comment?

  14. WVU to treat addictions with brain stimulationRead the original story w/Photo

    Wednesday Nov 15 | Logan Banner

    ... that major advances in brain scanning have also led to new treatments for movement disorders such as Parkinson's disease, and psychological afflictions including depression and severe anxiety. "One of our goals here is to do ultrasound-based ...

    Comment?

  15. Acorda halts enrollment in Parkinson's disease trialRead the original story w/Photo

    Wednesday Nov 15 | Channelnewsasia.com

    REUTERS: Acorda Therapeutics Inc said on Wednesday it has halted enrolling patients in a late-stage trial testing its drug to treat Parkinson's disease, after reports of cases related to neutropenia, sepsis and death.

    Comment?

  16. Acorda Therapeutics' stock pummeled as drug study enrollment halted after patient deathsRead the original story w/Photo

    Wednesday Nov 15 | MarketWatch

    ... trade Wednesday, after the biopharmaceutical company said it halted new enrollment for studies of its Parkinson's disease treatment tozadenant following some patient deaths. The company said of the 890 patients exposed to tozadenant in phase 3 and ...

    Comment?

  17. Nanowires could be potential drug delivery tools for neurodegenerative diseasesRead the original story w/Photo

    Wednesday Nov 15 | Medical News

    ... and Parkinson's. The international team has also demonstrated efficacy of this treatment on a Parkinson's disease model after traumatic brain injury. "We believe titanate nanowires could be considered as potential drug delivery tools for ...

    Comment?

  18. Acorda Therapeutics stops enrollment in long-term studies of...Read the original story w/Photo

    Wednesday Nov 15 | Seeking Alpha

    Acorda Therapeutics stockholders are facing an ugly day after the company announced five deaths in its Phase 3 program of Parkinson's disease candidate tozadenant. The fatalities were caused by sepsis, including four cases of agranulocytosis, the absence of infection-fighting white blood cells, that were possibly treatment-related.

    Comment?

  19. Michael Landsberg shares his mental health story at Wilmot event:The...Read the original story w/Photo

    Tuesday Nov 14 | The Waterloo Region Record

    ... for TSN. This leaves the rest of his day open to work with Sick Not Weak and spread his message. "How is Parkinson's disease considered a disease but mental illness not?" said Landsberg. "It's a disease of the brain, and if you're not thinking about ...

    Comment?

  20. Living Cell Technologies to hold board strategy meeting in DecemberRead the original story w/Photo

    Wednesday Nov 15 | NBR Newsroom

    Living Cell Technologies will continue to evaluate data from its recent clinical trial before holding a board strategy meeting in December, chief executive Ken Taylor told shareholders at the annual general meeting. Earlier this week, the ASX-listed Kiwi biotech firm saw its market capitalisation tumbled to A$20 million from about A$160 million when it said its latest trial didn't show a "statistically significant difference" between people who received its treatment for Parkinson's disease and a control group, something one shareholder said was a "colossal amount."

    Comment?